Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276848 | 1.00 | RECQL (0.54) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL8056889 | 1.00 | RECQL (0.54) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL12902 | 0.89 | ALDH1A1 (0.56) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL12908 | 0.89 | ALDH1A1 (0.56) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL771303 | 0.89 | ALDH1A1 (0.56) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL13319 | 0.89 | HPGD (0.60) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL10279194 | 0.89 | NR1H2 (0.57) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL23394146 | 0.88 | HPGD (0.56) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL8288407 | 0.88 | HPGD (0.56) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| Ammonia Solution, Strong SCHEMBL28293215 | 0.87 | HPGD (0.58) | RECQLUSP2SMN1; SMN2HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | RECQL 4828/4885USP2 3015/4885SMN1; SMN2 208/4885 |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | RECQL 3506/4885USP2 1286/4885SMN1; SMN2 4120/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | RECQL 372/4885USP2 2620/4885SMN1; SMN2 3713/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RECQL 2774/4885USP2 4825/4885SMN1; SMN2 289/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | RECQL 2761/4885USP2 4821/4885SMN1; SMN2 272/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RECQL 2774/4885USP2 4825/4885SMN1; SMN2 289/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | RECQL 4828/4885USP2 3015/4885SMN1; SMN2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.